Hearing preservation in cochlear implantation and drug treatment

Advances in Oto-Rhino-Laryngology

Volumn 67, Issue , 2010, Pages 6-13

  Barriat, Sebastien ^a   Poirrier, Annelise ^a   Malgrange, Brigitte ^a   Lefebvre, Philippe ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID;

COCHLEA PROSTHESIS; HEARING LOSS; HUMAN; IMPLANTATION; METHODOLOGY; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

COCHLEAR IMPLANTATION; COCHLEAR IMPLANTS; GLUCOCORTICOIDS; HEARING LOSS; HUMANS; TREATMENT OUTCOME;

EID: 77950348802     PISSN: 00653071     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000262592     Document Type: Article

References (63)

1. Lee KH, Cotanche DA: Potential role of bFGF and retinoic acid in the regeneration of chicken cochlear hair cells. Hear Res 1996;94:1-13.
2. Sliwinska-Kowalska M, Rzadzinska A, Rajkowska E, Malczyk M: Expression of bFGF and NGF and their receptors in chick's auditory organ following overexposure to noise. Hear Res 2005;210:93-103.
3. Umemoto M, Sakagami M, Fukazawa K, Ashida K, Kubo T, Senda T, et al: Hair cell regeneration in the chick inner ear following acoustic trauma: ultrastructural and immunohistochemical studies. Cell Tissue Res 1995;281:435-443.
4. Cristobal R, Popper P, Lopez I, Micevych P, De Vellis J, Honrubia V: In vivo and in vitro localization of brain-derived neurotrophic factor, fibroblast growth factor-2 and their receptors in the bullfrog vestibular end organs. Brain Res Mol Brain Res 2002;102:83-99.
5. Zhai SQ, Wang DJ, Wang JL, Han DY, Yang WY: Basic fibroblast growth factor protects auditory neurons and hair cells from glutamate neurotoxicity and noise exposure. Acta Otolaryngol 2004;124:124-129.
6. Zhai SQ, Cheng JC, Wang JL, Yang WY, Gu R, Jiang SC: Protective effect of basic fibroblast growth factor on auditory hair cells after noise exposure. Acta Otolaryngol 2002;122:370-373.
7. Yamasoba T, Altschuler RA, Raphael Y, Miller AL, Shoji F, Miller JM: Absence of hair cell protection by exogenous FGF-1 and FGF-2 delivered to guinea pig cochlea in vivo. Noise Health 2001;3:65-78.
8. Malgrange B, Rigo JM, Coucke P, Thiry M, Hans G, Nguyen L, et al: Identification of factors that maintain mammalian outer hair cells in adult organ of Corti explants. Hear Res 2002;170:48-58.
9. Ernfors P, Duan ML, ElShamy WM, Canlon B: Protection of auditory neurons from aminoglycoside toxicity by neurotrophin- 3. Nat Med 1996;2:463-467.
10. Shinohara T, Bredberg G, Ulfendahl M, Pyykko I, Olivius NP, Kaksonen R, et al: Neurotrophic factor intervention restores auditory function in deafened animals. Proc Natl Acad Sci USA 2002;99:1657-1660.
11. Zheng JL, Stewart RR, Gao WQ: Neurotrophin- 4/5, brain-derived neurotrophic factor, and neurotrophin-3 promote survival of cultured vestibular ganglion neurons and protect them against neurotoxicity of ototoxins. J Neurobiol 1995;28:330-340.
12. Silos-Santiago I, Fagan AM, Garber M, Fritzsch B, Barbacid M: Severe sensory deficits but normal CNS development in newborn mice lacking TrkB and TrkC tyrosine protein kinase receptors. Eur J Neurosci 1997;9:2045-2056.
13. Schimmang T, Alvarez-Bolado G, Minichiello L, Vazquez E, Giraldez F, Klein R, et al: Survival of inner ear sensory neurons in trk mutant mice. Mech Dev 1997;64:77-85.
14. Agerman K, Canlon B, Duan M, Ernfors P: Neurotrophins, NMDA receptors, and nitric oxide in development and protection of the auditory system. Ann NY Acad Sci 1999;884:131-142.
15. Fritzsch B, Tessarollo L, Coppola E, Reichardt LF: Neurotrophins in the ear: their roles in sensory neuron survival and fiber guidance. Prog Brain Res 2004;146:265-265-278.
16. Clough RL, Sud R, Davis-Silberman N, Hertzano R, Avraham KB, Holley M, et al: Brn-3c (POU4F3) regulates BDNF and NT-3 promoter activity. Biochem Biophys Res Commun 2004;324:372-381.
17. Van de Water TR, Staecker H, Halterman MW, Federoff HJ: Gene therapy in the inner ear. Mechanisms and clinical implications. Ann NY Acad Sci 1999;884:345-360.
18. Barrs VR, Gunew M, Foster SF, Beatty JA, Malik R: Prevalence of autosomal dominant polycystic kidney disease in Persian cats and related-breeds in Sydney and Brisbane. Aust Vet J 2001;79:257-259.
19. Atwal JK, Massie B, Miller FD, Kaplan DR: The TrkB-Shc site signals neuronal survival and local axon growth via MEK and P13-kinase. Neuron 2000;27:265-277.
20. Scheper V, Paasche G, Miller JM, Warnecke A, Berkingali N, Lenarz T, et al: Effects of delayed treatment with combined GDNF and continuous electrical stimulation on spiral ganglion cell survival in deafened guinea pigs. J Neurosci Res 2009;87:1389-1399.
21. Takemura K, Komeda M, Yagi M, Himeno C, Izumikawa M, Doi T, et al: Direct inner ear infusion of dexamethasone attenuates noise-induced trauma in guinea pig. Hear Res 2004;196:58-68.
22. Slattery WH, Fisher LM, Iqbal Z, Friedman RA, Liu N: Intratympanic steroid injection for treatment of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg 2005;133:251-259.
23. Gianoli GJ, Li JC: Transtympanic steroids for treatment of sudden hearing loss. Otolaryngol Head Neck Surg 2001;125:142-146.
24. Xenellis J, Papadimitriou N, Nikolopoulos T, Maragoudakis P, Segas J, Tzagaroulakis A, et al: Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngol Head Neck Surg 2006;134:940-945.
25. Lautermann J, Sudhoff H, Junker R: Transtympanic corticoid therapy for acute profound hearing loss. Eur Arch Otorhinolaryngol 2005;262:587-591.
26. Silverstein H: Use of a new device, the MicroWick, to deliver medication to the inner ear. Ear Nose Throat J 1999;78:595-598, 600.
27. Van Wijk F, Staecker H, Keithley E, Lefebvre PP: Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss. Audiol Neurootol 2006;11:357-365.
28. Lefebvre PP, Staecker H: Steroid perfusion of the inner ear for sudden sensorineural hearing loss after failure of conventional therapy: a pilot study. Acta Otolaryngol 2002;122:698-702.
29. Kopke RD, Hoffer ME, Wester D, O'Leary MJ, Jackson RL: Targeted topical steroid therapy in sudden sensorineural hearing loss. Otol Neurotol 2001;22:475-479.
30. Herr BD, Marzo SJ: Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2005;132:527-531.
31. Borkholder DA: State-of-the-art mechanisms of intracochlear drug delivery. Curr Opin Otolaryngol Head Neck Surg 2008;16:472-477.
32. Nakagawa T, Ito J: Drug delivery systems for the treatment of sensorineural hearing loss. Acta Otolaryngol Suppl 2007:30-35.
33. Sheppard WM, Wanamaker HH, Pack A, Yamamoto S, Slepecky N: Direct round window application of gentamicin with varying delivery vehicles: a comparison of ototoxicity. Otolaryngol Head Neck Surg 2004;131:890-896.
34. Saijo S, Kimura RS: Distribution of HRP in the inner ear after injection into the middle ear cavity. Acta Otolaryngol 1984;97:593-610.
35. Staecker H, Li D, O'Malley BW Jr, Van De Water TR: Gene expression in the mammalian cochlea: a study of multiple vector systems. Acta Otolaryngol 2001;121:157-163.
36. Swan EE, Mescher MJ, Sewell WF, Tao SL, Borenstein JT: Inner ear drug delivery for auditory applications. Adv Drug Deliv Rev 2008;60:1583-1599.
37. Light JP, Silverstein H: Transtympanic perfusion: indications and limitations. Curr Opin Otolaryngol Head Neck Surg 2004;12:378-383.
38. Parnes LS, Sun AH, Freeman DJ: Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999;109:1-17.
39. Chandrasekhar SS, Rubinstein RY, Kwartler JA, Gatz M, Connelly PE, Huang E, et al: Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngol Head Neck Surg 2000;122:521-528.
40. Jackson LE, Silverstein H: Chemical perfusion of the inner ear. Otolaryngol Clin North Am 2002;35:639-653.
41. Hoffmann KK, Silverstein H: Inner ear perfusion: indications and applications. Curr Opin Otolaryngol Head Neck Surg 2003;11:334-339.
42. Chandrasekhar SS: Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol 2001;22:18-23.
43. Battista RA: Intratympanic dexamethasone for profound idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2005;132:902-905.
44. Choung YH, Park K, Shin YR, Cho MJ: Intratympanic dexamethasone injection for refractory sudden sensorineural hearing loss. Laryngoscope 2006;116:747-752.
45. Dallan I, Bruschini L, Nacci A, Bruschini P, Traino C, Rognini F, et al: Transtympanic steroids as a salvage therapy in sudden hearing loss: preliminary results. ORL J Otorhinolaryngol Relat Spec 2006;68:247-252.
46. Rauch SD: Intratympanic steroids for sensorineural hearing loss. Otolaryngol Clin North Am 2004;37:1061-1074.
47. Haynes DS, O'Malley M, Cohen S, Watford K, Labadie RF: Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope 2007;117:3-15.
48. Ryan AF, Harris JP, Keithley EM: Immune-mediated hearing loss: basic mechanisms and options for therapy. Acta Otolaryngol Suppl 2002;548:38-43.
49. Welling DB: Clinical evaluation and treatment of immune-mediated inner ear disease. Ear Nose Throat J 1996;75:301-305.
50. Froehlich F, Fried M, Gonvers JJ, Saraga E, Thorens J, Pecoud A: Association of Crohn's disease and Cogan's syndrome. Dig Dis Sci 1994;39:1134-1137.
51. Staecker H, Lefebvre PP: Autoimmune sensorineural hearing loss improved by tumor necrosis factor-alpha blockade: a case report. Acta Otolaryngol 2002;122:684-687.
52. Wang X, Truong T, Billings PB, Harris JP, Keithley EM: Blockage of immunemediated inner ear damage by etanercept. Otol Neurotol 2003;24:52-57.
53. Matteson EL, Fabry DA, Strome SE, Driscoll CL, Beatty CW, McDonald TJ: Autoimmune inner ear disease: diagnostic and therapeutic approaches in a multidisciplinary setting. J Am Acad Audiol 2003;14:225-230.
54. Hochman J, Blakley BW, Wellman M, Blakley L: Prevention of aminoglycoside- induced sensorineural hearing loss. J Otolaryngol 2006;35:153-156.
55. Rybak LP, Whitworth CA: Ototoxicity: therapeutic opportunities. Drug Discov Today 2005;10:1313-1321.
56. Sergi B, Fetoni AR, Ferraresi A, Troiani D, Azzena GB, Paludetti G, et al: The role of antioxidants in protection from ototoxic drugs. Acta Otolaryngol Suppl 2004;552:42-45.
57. Bird PA, Murray D: Cochlear implantation: a panacea for severe hearing loss? N Z Med J 2008;121:4-6.
58. James DP, Eastwood H, Rochordson RT, O'Leary SJ: Effects of round window dexamethosone on residual hearing in a guinea pig model of cochlear implantation. Audiol Neurotol 2008;13:86-96.
59. Eshraghi AA, Adil E, He J, Graves R, Balkany TJ, Van De Water TR: Local dexamethasone therapy conserves hearing in an animal model of electrode insertion trauma-induced hearing loss. Otol Neurotol 2007;28:842-849.
60. Huang CQ, Tykocinski M, Stathopoulos D, Cowan R: Effects of steroids and lubricants on electrical impedance and tissue response following cochlear implantation. Cochlear Implants Int 2007;8:123-147.
61. De Ceulaer G, Johnson S, Yperman M, Daemers K, Offeciers FE, O'Donoghue GM, et al: Long-term evaluation of the effect of intracochlear steroid deposition on electrode impedance in cochlear implant patients. Otol Neurotol 2003;24:769-774.
62. Paasche G, Bockel F, Tasche C, Lesinski- Schiedat A, Lenarz T: Changes of postoperative impedances in cochlear implant patients: the short-term effects of modified electrode surfaces and intracochlear corticosteroids. Otol Neurotol 2006;27:639-647.
63. Agterberg MJ, Versnel H, van Dijk LM, de Groot JC, Klis SF: Enhanced survival of spiral ganglion cells after cessation of treatment with brain-derived neurotrophic factor in deafened guinea pigs. J Assoc Res Otolaryngol 2009, E-pub ahead of print.